Exchange: NYSEMkt·Updated 07:54 PM EST
KAPA logo

KAPA Kairos Pharma Ltd.

$0.4359
$0.0211
(4.62%)
Today
Closed $0.4359
$0.0357
(8.19%)
After Hours
Mkt Cap$2.04M
Vol33,757.00

About KAPA

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
39

Bearish Sentiment

How do you feel about KAPA?

TraderBuckNKY
$KAPA I've been down on this stock for some time. Really down. I've been in it for almost 2 years and obviously encouraged and hopeful in the beginning.... However, it has been consolidating at this level for some time. If management was ever going to deliver something positive, I think it's going to happen in the next 30 days. Personally, I will probably DCA at this level ... it may be a buying opportunity here...
1
TraderBuckNKY
$KAPA - Three ongoing clinical programs ⎼ Phase 2 trial treating Prostate Cancer with NIH grant funding ⎼ Phase 1 trial in treating Non-Small Cell Lung Cancer –Non-dilutive, Donor funded ⎼ Cleared IND for Glioblastoma Strategic relationship with Cedars-Sinai Medical Center (ranked #2 hospital nationally in 2022-2023 US News and World Report) drives clinical trial efficiency (Costs and Enrollment), and streamlines therapeutic innovations Initial clinical development focuses on therapies to overcome cancer drug resistance, derisked with extensive safety studies and biomarker for potential response Extensive therapies to reverse immune suppression in our pipeline Extensive IP portfolio valid until 2035 to 2040 Our technologies target a high value, large market - a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market
1
TraderBuckNKY
$KAPA LOS ANGELES --(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces:... that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer therapies.
1
Lyn30
$KAPA This post for me to track the stock Big risk of delisting imo as per their pr Equity, $1 bid etc, no cash so on going dilution imo I will take chance if one time pump comes
Scorpole
$KAPA Investors are certainly raising questions regarding the data the company releases.

Advertisement|Remove ads.